Top Markets
#1 PulseChain PulseChain +48.38%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.13%
#3 Ergo Ergo +16.71%
#4 RedStone RedStone +15.09%
#5 MarsCoin MarsCoin +13.98%
#6 SkyAI SkyAI +10.27%
#7 Monad Monad +9.11%
#8 OPENLOOT OPENLOOT +8.82%
#9 Lighter Lighter +8.81%
#10 Solv Protocol xSolvBTC Solv Protocol xSolvBTC +8.41%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Rank in Stocks #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Share Price
$1.00
Last synced: 2023-06-01
Market Cap
$30.11M
Change (1 day)
2.04%
Change (1 year)
0.00%
Country
US
Trade Angion Biomedica Corp. (ANGN)

Category

Healthcare
Earnings for Angion Biomedica Corp. (ANGN)
Earnings in 2026 TTM: 0
According to Angion Biomedica Corp. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Angion Biomedica Corp. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH